GlassScriptPhysician profile
Lyle C Feinstein
NPI 1871589416
$116,044.39
in general payments reported to CMS, 2019-2025
14 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $17K · 2021: $16K · 2022: $15K · 2023: $2,240 · 2024: $126 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,058 · Food and Beverage: $779 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,058.00 |
| Food and Beverage | $779.34 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46,039.55 | 2019-2021 | |
| Celgene Corporation | $21,028.52 | 2019-2021 | |
| Amgen INC. | $18,154.69 | 2019-2025 | Blincyto, Blincyto |
| E.R. Squibb & Sons, L.L.C. | $15,212.82 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14,240.85 | 2019-2021 | |
| Astellas Pharma US INC | $392.95 | 2020-2023 | |
| Janssen Biotech, INC. | $372.10 | 2020-2025 | Carvykti, Rybrevant, Tecvayli |
| Genzyme Corporation | $267.33 | 2024-2025 | |
| Pfizer INC. | $105.89 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $83.03 | 2022-2023 | Clonoseq |
| Partner Therapeutics, INC. | $54.87 | 2020 | |
| Alexion Pharmaceuticals, INC. | $47.71 | 2021 | |
| Kite Pharma, INC. | $25.58 | 2025 | Yescarta |
| Genentech USA, INC. | $18.50 | 2023 | Venclexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyle Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.